News from Freeline


Freeline will be progressing to the second dose cohort in the MARVEL-1 study immediately with first patient dosing expected in mid-2022

News from Freeline2022-04-13T15:50:45+02:00

News from Sangamo Therapeutics


Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

News from Sangamo Therapeutics2022-02-08T16:29:44+01:00
Go to Top